CHICAGO — In this video, Mitchell Singstock, MD, discusses results of a retrospective study that evaluated genomic testing rates for prostate cancer and whether an AI model could improve risk stratification and testing eligibility.Findings, which were presented at ASCO Annual Meeting, showed the model demonstrated 100% accuracy in 2025 in recommending National Comprehensive Cancer